GHC3 Talks

“We have a huge commitment to get our vaccine — and I consider it the best of the best — to the poorest of the world.”Dr. Gregory Glen, President of Research & Development at Novavax joins the podcast to talk about their COVID-19 vaccine. Like those used for decades to protect against viral infections, such as shingles and hepatitis, Novavax's COVID-19 vaccine is protein-based. It presents a genuine alternative for those keen to be protected but wary of the newer vaccine technologies, like mRNA.In this episode, Dr. Glen describes Novavax's innovative methods, immunity stimulating adjuvant Matrix-M™, and how their vaccine differs from the others available. He reveals the hurdles faced conducting Novavax's two gold-standard clinical trials amidst the challenging landscape of evolving variants and shares the encouraging data produced.Currently authorized for use in countries throughout Europe and Asia, and pending emergency use authorization in the United States, Novavax has partnered with the Serum Institute of India to ramp up production. Together they have pledged 1.1 billion COVID-19 vaccine doses to the neediest parts of the world. A move that could, with hope, help accelerate our path out of this pandemic.Takeaways:01:33 — Elegant and effective: Just what makes the Novovax COVID-19 vaccine unique?05:43 — Conducting clinical trials amidst the challenging landscape of evolving variants.11:05 —Strain change strategy: developing a vaccine especially for Omicron.14:42 — Key partnerships to pledge 1.1 billion doses to the neediest parts of the world.18:54 — Diversity in gold-standard clinical trials.21:28 — More than COVID – collaborating to vaccinate against malaria.25:27 — What is Matrix-M™ adjuvant technology?Special guest:Dr. Gregory Glen, President of Research & Development at Novavax 

“It's a lesson from Bangladesh and research in global health that's helped almost every American family. I learned we can learn a lot from developing countries.”Public health security requires a global approach. It's a fact currently underscored by the COVID-19 pandemic, but one that Dr. Roger Glass, Global Health Expert and Director of the Fogarty Center at NIH has known for some time. In this episode, he talks with our hosts, Dr. Rob Breiman and Ken Berta, about the bidirectional benefits of investing in global health, the role the private sector can play, and the mission and achievements of the Fogarty Center.Takeaways:02:10 — Lessons for the developed world from the developing world06:00 — Fogarty invests in people and global health security09:30 — How AIDs prepared us to tackle COVID-1912:00 — Private sector's key role in global health18:30 — Scoping a research agenda to tackle climate change23:06 — Medicine is only good for you if you take it32:15 — A physician's dream toolTo hear more on global health work listen to our podcast with Dr. Rebecca Martin, “Global Investments, Domestic Dividends.”Special guest:Dr. Roger Glass, Global Health Expert and Director of the Fogarty Center at the National Institutes of Health (NIH)

““Imposing a travel ban on a handful of countries in Southern Africa does not reduce your chances of importing the virus … There is absolutely no scientific basis to close your borders to a handful of countries and still keep it open to others.”In this episode of GHC3 Talks, Professor Shabir Madhi of the University of the Witwatersrand in Johannesburg, South Africa discusses what we know about the Omicron variant so far. He explains that Omicron is more transmissible than Delta and more antibody evasive, but it will be a couple of weeks before we know if it is more virulent.He goes on to talk about the vaccination challenge in South Africa. While the country has secured supply, vaccination rates have stagnated at 55% of the over-50s and 20% of younger age groups. He cites multiple barriers to vaccination including electronic registration, apathy, misinformation, and mistrust of government.Finally, Professor Madhi highlights the damage caused to low-income countries by WHO failing to update recommendations in real time and by irrational travel bans from high-income countries.Takeaways:03:30 — Omicron – what we know, what we don't know, and how long we'll have to wait for answers.13:00 — Access and acceptance of COVID-19 vaccines in South Africa:  Supply is secure but uptake is disappointing for a number of reasons.21:04 — South Africa's previous harsh lockdowns achieved little and will have long-reaching negative impacts.24:16 — WHO failed to update lockdown recommendations in real time based on data. That came at a high cost for low-income countries.28:50 — The travel ban is futile. Closing your borders to a handful of countries does not reduce your risk of importing the virus30:15 — The contempt of high-income countries for countries in the south of Africa is obvious. They congratulate the expert and transparent science but are happy to destroy economies and livelihoods.34:00 — Mutations may be occurring in the immunocompromised.36:20 — How can we move away from a colonial approach to global health?

Spike and Surge are back! After an extended summer break filled with new adventures for them both, they return to the show to share their news. Joined by old friend and CHRISTUS St. Francis Cabrini Hospital CEO and President, Monte Wilson, they discuss the unintended consequences of COVID-19 for healthcare and what the future could hold.Takeaways:02:30 — The return of travel and the beginning of a long-postponed research project in Uganda to detect emerging zoonotic diseases and enhanced prevention and control.07:15 — A new job for Surge in Healthcare and Life Sciences technology.11:05 — No reason to be wary: collection of healthcare data is well protected and could lead to precision, personalized medicine.17:34 — Monte Wilson of CHRISTUS Health discusses the challenges COVID-19 and climate change have brought to Louisiana healthcare systems.19:56 — Consequences beyond COVID-19: Few ICU beds, nursing staff shortages and low vaccination rates have had lethal impacts for patients with diseases other than COVID-19.25:00 — Why are vaccination rates in Louisiana so low? A deadly mix of fear, suspicion, politics and religion.33:32 — Finding creative approaches, including technology, to address the shortage of nursing staff – a problem exacerbated not assisted by staffing agencies.39:15 — Success through telehealth and virtual care, but how do we retain the most important and human elements of care?42:26 — Collaboration is a differentiator.Special guest:Monte Wilson, President and CEO, CHRISTUS St. Francis Cabrini HospitalReferences:CHRISTUS St. Frances Cabrini Hospital (christushealth.org)Dr. David Holcombe, Public Health Medical Director for AlexandriaCutting for Stone by Abraham VergheseCenter for Forecasting and Outbreak Analytics, CDC

Against the backdrop of India's punishing second wave of COVID-19, Dr. Raches Ella of Bharat Biotech joins the podcast to talk about the company's pioneering work in vaccines. He discusses their own COVID-19 vaccine, Covaxin, the challenges India faces right now in administering vaccine to such a large population, and Bharat's innovative work in developing a respiratory vaccine to fight a respiratory virus.Takeaways:04:07 — When the virus hit, Bharat Biotech were well placed to respond. The result is Covaxin.09:58 — Just how effective are the vaccines against the COVID-19 variants of concern?15:30 — 20 million doses of Covaxin have been administered in India. While all production is currently mandated for domestic use, the only way out of the pandemic is equitable distribution of vaccine globally.18:36 — India leveraged its childhood vaccination program to roll out the COVID-19 vaccine.20:15 — As a country with high levels of infectious diseases, vaccine hesitancy is not really an issue in India.22:53 — Respiratory vaccine for a respiratory virus: Bharat Biotech have partnered with Washington University in St. Louis to develop an intranasal vaccine. Currently in trials and hoping for release by the end of this year.26:12 — What can the world do right now to help India? A great start would be standardized protocols for treating and managing COVID-19 from the WHO.31:10 — Beyond COVID-19: Bharat Biotech are also working on vaccines for polio, cholera and chikungunya.Special guest:Raches Ella, MBBS, MS, Head of Business Development & Advocacy and Project Lead for Sars COV2 vaccine 

As India battles a catastrophic second COVID-19 surge. Dr. Venkat Narayan, Professor of Global Health and Epidemiology and Professor of Medicine at Emory University joins our podcast. He talks about how this pandemic has shown the world the importance of responsible, ethical leadership, strong science, open data, preparedness, and collaboration across borders.Takeaways:06:10 — The three factors that made COVID-19 the perfect example of a syndemic.08:28 — India looked like it was weathering the COVID storm. What went wrong?15:00 — The pandemic has shown the need for responsible, ethical leadership, strong science, open data, and preparedness.15:31 — India's vaccination challenge. India manufactures 60-70% of the world's vaccines. Yet only 2% of India's population is fully COVID vaccinated. With a population of 1.4 billion, reaching herd immunity will require 10-15 million vaccinations daily.24:05 — India has the infrastructure to manage this – from vaccine manufacturers to a civil service and rail network but this effort will need very skilled collaboration, coalitions and coordination.30:00 — India needs a central vaccine communication center – vaccine reluctance can be combatted with sensitive, consistent messaging.32:15 — The healthcare system is stretched to its limits. The lesson to learn here is listen to the data: it provides a window to prepare and plan. 44:20 — This virus does not respect societal biases. It infects all, regardless of age, gender, race, or religion. Special guest:K. M. Venkat Narayan, MD, MSc, MBA | EGDRC | Emory University 

Dr. Rob Breiman and Ken Berta are joined by Professor Dame Sally Davies, the U.K.'s Special Envoy for Antimicrobial Resistance, and Andrew Staunton, HM Consul General in Atlanta, to talk about the urgent public health challenge posed by antimicrobial resistance (AMR). With the use of antibiotics and deaths from drug-resistant infections rising, Dame Sally and Andrew discuss the essential steps that need to be taken to highlight and arrest this silent pandemic.Takeaways:06:00 — Without action, the death rate from drug resistant infections per year is predicted to reach 10 million by 2050.07:00  — As low- and middle-income countries are disproportionately affected by AMR, a sharp focus on investment and development is crucial.09:24  — Antibiotic effluence contaminates the environment, and fish farming is one of the biggest culprits.13:23  — AMR is a silent and creeping pandemic. We must communicate more effectively and broadly about the dangers.14:57 — To combat antimicrobial resistance, we need to begin with surveillance, better drug stewardship, examination of the food chain, and promotion of pharmaceutical innovation.18:57 — The impact of COVID-19 on AMR.22:18 — In a world of urbanization, global warming, climate change and COVID-19, why should people worry about antimicrobial resistance?26:29 — The private sector has a critical role to play.34:25 — Communication, education and engagement on AMR at the community level.38:38 — Finding the access versus excess balance.Special Guests:Professor Dame Sally Davies, U.K. Special Envoy on Antimicrobial Resistance and Master of Trinity College, Cambridge Andrew Staunton, HM Consul General in AtlantaReferences:The Trinity ChallengeInvestor Action on AMRThe Fleming FundJim O'Neill, Economist

Dr. Rebecca Martin, Director of CDC's Center for Global Health (CGH), joins this episode to discuss their recently published Outbreaks Report and the important work CGH is doing around the world. She highlights several of the Center's programs, including the Field Epidemiology Training Program which has taught over 18,000 Disease Detectives to lead prevention, detection and response in more than 90 countries. Now the most experienced of those countries have begun to mentor others through crises.Dr. Martin goes on to talk about the impact of COVID-19 on the Center's programs, especially critical initiatives like measles and polio vaccination. She describes the Center's mission as “working globally to domestically.” The symbiotic nature of that mission has become increasingly apparent during this pandemic, as the lessons learned abroad are now helping to inform the response to COVID-19 at home.Takeaways:03:39 —The Center for Global Health's history, mission and 10-year anniversary successes.06:46 — Disease detectives: over 18,000 health professionals in 90 countries trained to lead prevention, detection and response.11:49 — How CGH programs have adapted and innovated in the face of COVID-19.18:15 — The impact of suspending programs due to COVID-19. The collateral damage from program suspension could have been greater than the virus itself.22:37 — What the next ten years holds for the Center for Global Health.24:51 — Three key examples of how investing in public health overseas has taught the U.S. valuable lessons that can be implemented at home.31:40 — Partnerships are key. This work cannot be completed alone.38:04 — Has the pandemic taught us to value equity?References:CDC - Global Health CDC 2021 Outbreak Report 

Towards the end of last year, our co-host Ken Berta (aka Surge) contracted COVID-19. Determined to add to our pool of knowledge on the virus and provide a resource for others, he kept a diary of his experience. In this episode, he talks candidly to fellow host, Dr. Rob Breiman (aka Spike) about his battle with COVID-19. Takeaways:02:00 — Keeping a COVID diary. To document this disease, sharing our COVID experiences is critical. We all want to know what is going to happen next and what we should do when.05:09 — Day One - The first symptoms and self-isolation: fatigue, muscle aches, and joint pain.09:22 — Tests – not so easy to take and tough to sit through.12:35 — Round two of symptoms: cough, migraine, nausea, low oxygen levels, chest constriction, and finally, the fever.16:00 — Mitigation methods or how to stay out of hospital.17:33 — Day Five - The symptoms compound and worsen, the delirium begins, but worst of all is not knowing what to do or whom to turn to for advice.20:50 — Day Seven – loss of taste and smell22:00 — Retracing the steps to exposure.24:00 — The virus spreads to other family members.27:20 — Eli Lilly monoclonal antibody trial.33:00 — Lessons learned? Isolate, drink fluids, try to stay mobile, do breathing exercises, know where to go to get tested.ReferencesWhat is bamlanivimab | Antibody Drug | Lilly COVID-19 TreatmentRegeneron's COVID-19 Response Efforts

Having received several queries and questions from our listeners, in this episode Dr. Rob Breiman and Ken Berta, aka Spike and Surge, set out to provide some answers. They discuss trust in vaccines, COVID virus mutation, safely reopening schools and businesses, and the mitigations we'll need to keep as the vaccine rolls out.References:Different COVID-19 Vaccines | CDC U.S. Food and Drug Administration (fda.gov) WHO | World Health Organization Gavi, the Vaccine AllianceU.S. Health Resources & Services Administration | (hrsa.gov)When to Test - COVID-19 Testing Impact CalculatorHome· Starter Portal (globalhealthc3.org)Global Health Crisis Coordination Center - Vaccine Tracker (globalhealthc3.org)Global Health Crisis Coordination Center - Back 2 Work (globalhealthc3.org)Global Health Crisis Coordination Center - Back 2 School (globalhealthc3.org)

“I think healthcare is a right; everyone should have options”In this episode of GHC3 Talks, Kathy McNamara, Associate Vice President of Clinical Affairs for the National Association of Community Health Centers joins our hosts, Dr. Rob Breiman (Spike) and Ken Berta (Surge), on the podcast.They talk about how the community health centers have responded to the challenges posed by COVID-19 and the burnout faced by dedicated staff who have been on the frontline since March.In discussing the preparations needed to distribute a vaccine, Kathy highlights the importance of moving from macro to micro planning at the community level and the critical need for tailored messaging to be delivered by trusted members of the community.Takeaways:03:57 — COVID-19 did not change the needs of patients, but the care delivery models had to.06:27 — Concerned about serving communities but also about taking care of the compassionate care chain who has been on the front line since March07:11 — Trust is key and health centers have been building relationships with families over several generations.11:42 — They have seen a lot of macro planning, but the focus needs to turn to micro planning at the community level.16:26 — Communication is key, and it needs to be tailored to the audience and be delivered by trusted sources19:52 — Some of these communities are more worried about their own socioeconomic issues than they are COVID and vaccination.28:50 — Introducing GHC3's Priority-based use of Allocated Vaccines Estimator (PAVE). A tool intended to aid health professionals with immunization program planning and vaccine distribution.Special guests:Kathy McNamara, Associate Vice President of Clinical Affairs of the National Association of Community Health CentersReferences:NACHCGHC3's Priority-based use of Allocated Vaccines Estimator (PAVE)

“Investing in communications research is important. We need to understand who is hesitant, why they're hesitant, whom do they trust as messengers, and what is it they really want to hear that would convince them it's worth taking the vaccine.”While the world watches and waits for a COVID vaccine to be reviewed and approved, Dr. Rob Breiman and Ken Berta, otherwise known as Spike and Surge, sit down with Dr. Walt Orenstein, Associate Director of the Emory Vaccine Center and Professor of Medicine, Pediatrics, Public Health and Epidemiology at Emory University and former Director of the U.S. National Immunization Program. They talk about what we should be looking for in the vaccine trial data and, perhaps more importantly, how we can persuade people to trust it.03:00 — The focus for the first round of vaccination. Where will you be in line?09:48 — A vaccine that stays in the vial is 0% effective.10:40 — Papers not press releases – what should we be looking for in the vaccine trial data?14:16 — Communication is key to combatting vaccine hesitancy. 16:49 — A one-size-fits-all approach to messaging simply won't work.18:30 — The COVID-19 vaccine shows the incredible technological advance in vaccine development. We aren't cutting corners, we're just getting better at what we do.23:05 — What are the challenges in trying to immunize the whole world, and how can we combat them?31:12 — Global vaccination will benefit poorer countries, and richer ones too.Special Guest:Walter A. Orenstein, MD (emory.edu)References:U.S. Food and Drug Administration (fda.gov) VRBPAC – CDC Vaccine and related biological products advisory committee  Advisory Committee on Immunization Practices (ACIP) | CDC

In this episode of GHC3 Talks, Dr. Rob Breiman and Ken Berta are joined by Dr. Dan Salmon of John Hopkins University School of Public Health. In the wake of recent vaccine press releases, they discuss how to build trust in the COVID-19 vaccines, why that is important, and the crucial role that messaging will play."It's much easier to help form views through information and knowledge and science than it is to change them once they're existing. So we need to be a part of teaching people, educating people and creating the mindset. "Takeaways:02:14 — Vaccines are a victim of their own success.04:18 — Vaccine acceptance will move at the speed of trust.13:55 — Educating amidst a world of misinformation is a challenge, so messaging is key.14:41 — People's trust in the vaccines is just as important as the vaccines' effectiveness.19:03 — Thorough regulatory review is critical to the safety, acceptance and trust in these vaccines.22:45 — Vulnerable populations who need the vaccine may be reluctant to be first in line due to historic mistreatment and exploitation.25:25 — Mass vaccination programs are in danger of being undermined by safety scares.28:10 — Studies need to be credible, but more importantly believed by the public.Special Guests:Dr. Dan Salmon, Professor and Director, Institute for Vaccine Safety, Johns Hopkins University School of Public HealthReferences from this episode:Dr. Helene GayleFood & Drug Administration Agency (FDA)Vaccine and Related Biological Products Advisory Committee (VRBPAC)

Welcome to the GHC3 podcast, we are excited you found us. In each episode you will hear our hosts explore crises affecting humanity and the planet. They will discuss, with assorted guests,  how what we learn when dealing with challenges teaches us how to be more smart, resilient, resourceful, and ethically evolved as a species … in short, how we can become stronger as a civilization.In this, the inaugural episode of the GHC3 podcast, our hosts Ken Berta and Dr. Rob Breiman discuss the complex and multifaceted issues surrounding COVID-19 vaccination. To help tackle this topic, they are joined by two special guests: Jim Lavery, Professor of Global Health Ethics at Emory University and Dr. Theresa Cullen, Director of Pima County Public Health Department.Jim shines a light on the role ethics could, and should, play in the prioritization of vaccine allocation, while Dr. Theresa Cullen underlines the need for community collaboration and data-driven decisions.Takeaways:01:54 — The WHO is still the leading voice – and that voice says a vaccine is not a silver bullet.07:55 — Production of a safe and effective vaccine may turn out to be the easy part.12:42 — How ethics can help us understand the problems we face.16:50 — Vaccine allocation models: the WHO model versus the Fair Priority Model.19:40 — The last mile of distribution will determine how vaccine equity is perceived.25:05 — What are the ethical goals in equitable distribution?28:14 — Technology is producing vaccine at an unprecedented rate, but its only worth it if people receive a shot in the arm.31:20 —  We have to approach this pandemic as an opportunity and recognize the solution lies in collaboration: our success depends upon each other.38:05 — The haunting question is who will get what and how will we decide?43:22 —  The ultimate public health goal? Data-driven decisions that guide integrated health and human services.47:04 — Just who are Spike and Surge?Our hosts:Ken Berta, Executive Director, GHC3Dr. Rob Breiman, Epidemiologist and Chief Scientist, GHC3, and Professor, Global Health, Environmental Health and Infectious Diseases, Emory UniversitySpecial Guests:Jim Lavery, Conrad N. Hilton Chair in Global Health Ethics, Emory UniversityDr. Theresa Cullen, Director of Pima County Public Health DepartmentReferences from this episode:Emory University, Center for EthicsPima County Health DepartmentWHOGAVIThe Fair Priority Model